SLEIPNIR clinical trial platform to test 3 Parkinson’s drugs at once
Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments…
Articles by Andrea Lobo
Study reinforces inflammation’s role in Parkinson’s development
Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to…
Apathy treatment IRL757 found safe in multiple doses
Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a…
Montara to develop LRRK2 inhibitor drug for Parkinson’s
The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop…
Sensors, machine learning used in movement disorder diagnosis
Integrating movement sensors and machine learning approaches may aid a correct diagnosis of movement disorders, including essential tremor and myoclonus,…
Parkinson’s Foundation names new accredited exercise providers
The Parkinson’s Foundation now recognizes Dance for PD and Parkinson’s Pointe as accredited exercise education providers, a…
Gene therapy AAV-GAD wins RMAT designation for Parkinson’s
The U.S. Food and Drug Administrated (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to AAV-GAD, MeiraGTx’s gene…
Students aim to boost diversity in Parkinson’s exercise providers
Two University of Michigan-Flint doctorate students received a $50,000 grant to support diversity among exercise providers offering care to people…
AI tools may help detect, diagnose Parkinson’s at early stages: Study
Using advanced diagnostic tools — such as different types of brain scans and methods that employ artificial intelligence (AI) —…
MJFF expands training program for movement disorder specialists
The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship…